Managers / Q4 2022 · view latest →
GENEVA CAPITAL MANAGEMENT LLC
CIK 0001009232 · 411 EAST WISCONSIN AVE, SUITE 2320, MILWAUKEE, WI, 53202 · 4142246002
Summary
Geneva Capital Management LLC reported $4.5B in U.S.-listed holdings across 331 positions for Q4 2022.
Its largest position, FICO, represents 2.3% of the portfolio.
Compared with Q3 2022, the fund opened 3 new positions and exited 7.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Other · 51.8% · $2.3B
- Common Stock · 47.8% · $2.1B
- ETP · 0.4% · $18M
Quarter-over-Quarter Changes full breakdown →
vs Q3 2022 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| STERIS PLC USD | NEW | +139.7K | 139.7K | +$26M | $26M |
| VANGUARD SMALL-CAP GROWTH INDE | NEW | +14.5K | 14.5K | +$3M | $3M |
| SPGIS&P GLOBAL INC | NEW | +3.9K | 3.9K | +$1M | $1M |
| BIO-TECHNE CORP | ADDED | +793.1K | 1.06M | +$12M | $88M |
| ISHARES TR RUS 2000 GRW ETF | ADDED | +37.3K | 52.4K | +$8M | $11M |
| LHC GROUP INC | SOLD OUT | −215.4K | 0 | −$35M | $0 |
| STERIS PLC USD | SOLD OUT | −137.1K | 0 | −$23M | $0 |
| ABMDEURABIOMED INC | SOLD OUT | −89.2K | 0 | −$22M | $0 |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q4 2022
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $4.7B | 252 | May 6, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $5.3B | 257 | Feb 12, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $5.8B | 255 | Nov 13, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $6.0B | 258 | Aug 5, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $5.4B | 261 | May 9, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $5.8B | 270 | Feb 6, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $6.0B | 272 | Nov 5, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $5.5B | 270 | Aug 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $5.7B | 230 | May 3, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $5.3B | 230 | Feb 7, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $4.7B | 229 | Nov 13, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $5.1B | 223 | Aug 1, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $4.9B | 225 | May 15, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $4.5B | 331 | Feb 7, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $4.3B | 293 | Nov 2, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $4.3B | 289 | Aug 2, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $5.2B | 292 | May 2, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $6.2B | 286 | Feb 2, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $5.9B | 292 | Nov 8, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $6.1B | 293 | Aug 11, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $5.9B | 235 | May 3, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $5.9B | 231 | Feb 2, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $4.8B | 225 | Nov 12, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $4.6B | 221 | Aug 13, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $3.5B | 223 | May 15, 2020 | 13F-HR | changes · EDGAR ↗ |
Other Included Managers
This filing reports holdings on behalf of 3 additional managers.
- Bank of New York Mellon Corp028-12592
- Nationwide Fund Advisors028-05161
- Wilmington Trust, National Association028-14686
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.